My Treatment Approach: Metastatic Castration-Resistant Prostate Cancer

Andrew Armstrong, MD, and Matthew Manning, MD, explain how the treatment options and typical patient outcomes in mCRPC have changed over history.

Medical oncologist Andrew Armstrong, MD, details the available treatment options for patients with mCRPC, and how recommendations vary by prior therapy and mutation status.

Dr Andrew Armstrong presents a profile of a 78-year-old man with mCRPC with a single PSMA-avid bone metastasis and asks Dr Manning how he would treat the patient in question.

Drs Manning and Armstrong discuss the best treatment approaches for a patient with mCRPC and disease progression in the bone after initial radiotherapy for metastatic disease.

Radiation oncologist Matthew Manning, MD, shares the patient profile of a 72-year-old man with mCRPC receiving palliative treatment with radium-223.

Drs Armstrong and Manning review the safety and efficacy data from the ALSYMPCA trial of radium-223 in patients with mCRPC.

A medical oncologist and radiation oncologist share clinical insight on how they might approach subsequent treatment selection in patients with mCRPC who have disease progression on or after radium-223.

Centering discussion on a patient profile of mCRPC with asymptomatic bone metastases, experts share best approaches to treating and optimizing outcomes for such patients, including supplement recommendations to prevent bone fractures.

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.

Matthew Manning, MD, and Andrew Armstrong, MD, discuss the remaining unmet needs in mCRPC, clinical trials and novel agents to look out for, and share practical advice for other clinicians treating patients with the disease.